Zolpidem Tartrate Patent Expiration
Zolpidem Tartrate was first introduced by Cosette Pharmaceuticals Inc
Zolpidem Tartrate Patents
Given below is the list of patents protecting Zolpidem Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zolpimist | US8236285 | Buccal, polar and non-polar spray containing zolpidem | Aug 07, 2032 | Aytu |
| Edluar | US9265720 | Pharmaceutical formulations useful in the treatment of insomnia | Feb 25, 2031 | Viatris |
| Intermezzo | US8242131 | Methods of treating middle-of-the-night insomnia | Aug 20, 2029 | Purdue Pharma |
| Intermezzo | US7658945 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof | Apr 15, 2027 | Purdue Pharma |
| Edluar | US9597281 | Pharmaceutical formulations useful in the treatment of insomnia | Apr 06, 2027 | Viatris |
| Intermezzo | US7682628 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Feb 16, 2025
(Expired) | Purdue Pharma |
| Intermezzo | US8252809 | Compositions for treating insomnia |
Feb 16, 2025
(Expired) | Purdue Pharma |
| Ambien Cr |
US6514531 (Pediatric) | Controlled-release dosage forms comprising zolpidem or a salt thereof |
Jun 01, 2020
(Expired) | Cosette |
| Ambien Cr | US6514531 | Controlled-release dosage forms comprising zolpidem or a salt thereof |
Dec 01, 2019
(Expired) | Cosette |
| Edluar | US6761910 | Pharmaceutical composition for the treatment of acute disorders |
Sep 24, 2019
(Expired) | Viatris |
| Edluar | US8512747 | Pharmaceutical composition for the treatment of acute disorders |
Sep 24, 2019
(Expired) | Viatris |
| Zolpimist | US7632517 | Buccal, polar and non-polar spray containing zolpidem |
Oct 01, 2017
(Expired) | Aytu |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Zolpidem Tartrate's patents.
Latest Legal Activities on Zolpidem Tartrate's Patents
Given below is the list recent legal activities going on the following patents of Zolpidem Tartrate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 15 Jan, 2018 | US7632517 |
| Expire Patent Critical
| 02 Sep, 2016 | US8236285 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 09 Apr, 2014 | US7632517 |
| Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical
| 09 Apr, 2014 | US7632517 |
| Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical
| 09 Apr, 2014 | US7632517 |
| Petition to Accept Late Payment of Maintenance Fee Payment Filed Critical
| 09 Apr, 2014 | US7632517 |
| Expire Patent Critical
| 10 Jan, 2014 | US7632517 |
| Patent Issue Date Used in PTA Calculation Critical
| 07 Aug, 2012 | US8236285 |
| Recordation of Patent Grant Mailed Critical
| 07 Aug, 2012 | US8236285 |
| Issue Notification Mailed Critical
| 18 Jul, 2012 | US8236285 |
Zolpidem Tartrate's Family Patents
